Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,458JPY
22 Jul 2016
Change (% chg)

¥-54 (-1.20%)
Prev Close
¥4,512
Open
¥4,476
Day's High
¥4,512
Day's Low
¥4,424
Volume
2,124,000
Avg. Vol
2,685,044
52-wk High
¥6,609
52-wk Low
¥4,098

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.72
Market Cap(Mil.): ¥3,523,349.00
Shares Outstanding(Mil.): 790.34
Dividend: 90.00
Yield (%): 4.04

Financials

  4502.T Industry Sector
P/E (TTM): 44.09 36.15 37.05
EPS (TTM): 101.11 -- --
ROI: 2.73 15.11 14.35
ROE: 3.92 16.17 15.56

BRIEF-Fujifilm to bid for Takeda's research reagents unit - Nikkei

* Fujifilm Holdings is set to make an offer for a laboratory chemicals unit of Takeda Pharmaceutical - Nikkei

Jul 21 2016

Court dismisses Takeda's bid to block Hikma gout drug sales

By Brendan Pierson A federal appeals court has dismissed a bid by Takeda Pharmaceutical Co to halt sales of Hikma Pharmaceuticals PLC's gout drug Mitigare, which has the same active ingredient as Takeda's Colcrys.

Jul 15 2016

BRIEF-Takeda receives EC approval of adcetris for post-transplant hodgkin lymphoma

* Takeda receives European Commission approval of adcetris (brentuximab vedotin) for consolidation treatment in post-transplant hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 06 2016

BRIEF-Takeda Pharmaceutical, Altos Therapeutics to develop Altos's ATC-1906

* Co, Altos Therapeutics have entered into agreement to further development of Altos's proprietary compound ATC-1906

Jul 01 2016

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.

Jun 09 2016

BRIEF-Takeda, Roivant Sciences launch Myovant Sciences to develop therapeutics for women's health, prostate cancer

* Roivant Sciences and Takeda launch Myovant Sciences to develop therapeutics for women's health and prostate cancer

Jun 06 2016

BRIEF-Takeda Pharmaceutical Co Ltd receives positive CHMP opinion for ADCETRIS

* Takeda receives positive CHMP opinion for ADCETRIS as consolidation treatment in post-transplant hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 27 2016

Valeant rejected joint takeover bid from Takeda, TPG in spring: source

Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP [TPG.UL] this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

UPDATE 2-Valeant rejected joint takeover bid from Takeda, TPG in spring - source

May 26 Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

BRIEF-Valeant received joint takeover approach from Takeda, TPG before Joseph Papa became CEO - source

* Valeant received joint takeover approach from Takeda, TPG a few weeks before Joseph Papa became CEO - Source Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 26 2016

Earnings vs. Estimates